Skip to main content

11-10-2017 | Psoriatic arthritis | Case report | Article

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

Rheumatology and Therapy

Authors: Eleftherios Pelechas, Tereza Memi, Paraskevi V. Voulgari, Alexandros A. Drosos

Publisher: Springer Healthcare


Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab.

Please log in to get access to this content

Related topics

Image Credits